// App-Quantinova.ai

SAT0066 : BURDEN OF MALIGNANCY, VENOUS THROMBOEMBOLISM, ANEMIA, AND INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO SWITCHED FROM A FIRST CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG TO ANOTHER DISEASE-MODIFYING ANTIRHEUMATIC DRUG REGIMEN

Researchers

Presenter

  • R. K. Dore

Principal Investigators

  • J. Antonova

  • L. Chang

  • H. Huang

  • H. Kim

  • M. C. Genovese

Medical Centers

  • Robin K. Dore, MD, Private Practice, Tustin, United States of America

  • 1.Gilead Science Inc, Foster City, United States of America

  • IQVIA, Plymouth Meeting, United States of America

  • Stanford, Division of Immunology and Rheumatology, Stanford, United States of America

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Infectious Diseases (ID)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Rheumatoid arthritis

  • Shingles

  • Inflammatory Arthritis

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved